pemafibrate
Kowa Pharmaceuticals
[]
poster by et al. at #aha22 impact of 22y cumulative apob on ascvd in cardia
- similar risk from trl-p and ldl-p
- apob &gt; 0.80mg/dl per year a cut point of increased cv risk
prominent trial: trl-p offset by ldl-p (apob slightly ) - neutral result on outcomes. 
?? ? endorse; mostly health science posts